Opinion
Video
Author(s):
The panel outlines combination therapy options for patients with advanced prostate cancer and discusses the potential benefits of intensification of androgen deprivation therapy.
Study shows IsoPSA’s predictive ability for clinically significant prostate cancer
Dr. Murphy on increasing diversity in cancer clinical trials
Urologists perform first remote robot–assisted HIFU for prostate cancer
Dr. Schwen on focal therapies for prostate cancer
Study underway to assess 3-fraction SBRT regimen in prostate cancer
Polygenic risk score may identify more clinically significant PCa than PSA, MRI